Erratum in «High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil»
AUTOR(ES)
Vidal, José Ernesto, Song, Alice Tung Wan, Matos, Maria Laura, Bartmann, Daniel, Anjos, Guilherme dos, Miranda, Érique José Peixoto de, Freitas, Ângela Carvalho, Dalben, Mirian de Freitas, Santana, Claudinei, Segurado, Aluísio Cotrim, Barreto, Cláudia Cortese, Hernández, Adrián Vladimir
FONTE
Braz J Infect Dis
DATA DE PUBLICAÇÃO
2013-06
RESUMO
Documentos Relacionados
- High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil
- Long-term virologic and immunologic responses on darunavir/ritonavir - containing regimens among highly antiretroviral therapy-experienced patients: 7-year follow-up of a prospective cohort study in São Paulo, Brazil
- A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
- Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
- Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy
